European Journal of Obstetrics & Gynecology and Reproductive Biology 160 (2012) 170–173

Contents lists available at SciVerse ScienceDirect

European Journal of Obstetrics & Gynecology and Reproductive Biology

journal homepage: www.elsevier.com/locate/ejogrb

Timing of fertility preservation procedures in a cohort of female patients with cancer

Esther Jenninga [a,1], Leoni A. Louwe [a,*], Alexander A.W. Peters [a], Johan W.R. Nortier [b], Carina G. Hilders [c]

[a] Department of Gynecology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands
[b] Department of Clinical Oncology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands
[c] Department of Gynecology, Reinier de Graaf Hospital, Reinier de Graafweg 3-11, 2625 AD Delft, The Netherlands

ARTICLE INFO

Article history:
Received 5 November 2010
Received in revised form 6 October 2011
Accepted 9 November 2011

Keywords:
Women
Cancer
Fertility preservation
Ovarian tissue cryopreservation
Embryo cryopreservation

ABSTRACT

Objective: Comparison of time intervals from diagnosis to chemotherapy between patients opting for embryo cryopreservation or ovarian tissue cryopreservation.
Study design: Retrospective analysis.
Setting: University hospital in the Netherlands.
Patients and methods: Thirty-five female patients undergoing fertility preservation procedures before treatment with chemotherapy for cancer. Embryo cryopreservation was performed in 12 patients and ovarian tissue cryopreservation in 23 patients. We investigated differences in time intervals (from diagnosis to start of chemotherapy) between patients opting for embryo cryopreservation and patients opting for ovarian tissue cryopreservation. We calculated time intervals between the moment of diagnosis, the moment of referral, the moment of consultation, the moment of finishing of the fertility preservation procedure and the start of chemotherapy.
Results: The median time between diagnosis and referral (median = 18 days) and between referral and consultation (median = 5 days) was comparable in both groups. A significant difference was found between ovarian tissue cryopreservation and embryo cryopreservation for the time interval between consultation and cryopreservation ($p = 0.001$). Ovarian tissue cryopreservation was completed for half of the patients within 6 days after consultation with the gynecologist, and the hormonal stimulation for embryo cryopreservation was completed for all patients within four weeks (median = 18 days), with a median of 11 days of hormonal stimulation. A significant difference was found between ovarian tissue cryopreservation and embryo cryopreservation in the time interval between fertility preservation and start of chemotherapy (median = 7 vs 19 days, $p = 0.019$). In sum, the total duration between diagnosis and chemotherapy was significantly shorter for ovarian tissue cryopreservation patients than for embryo cryopreservation patients (median = 47 vs 69 days, $p = 0.042$).
Conclusion: Embryo cryopreservation can be performed within the standard timeframe of cancer care in patients with breast cancer receiving adjuvant chemotherapy, but if delay of the start of chemotherapy is harmful, ovarian tissue cryopreservation can be done within one week.

1. Introduction

As a result of improvement in oncological treatments, most young cancer patients achieve prolonged survival in which quality of life issues are emphasized [1–3]. In particular, the consequences for family planning due to premature ovarian failure are of major concern in premenopausal women. Multidrug chemotherapy, especially with alkylating agents, radiation therapy or surgery can permanently or temporarily impair future fertility [4]. The risk of premature ovarian failure depends mainly on the age of the patient, the type and dose of chemotherapy, and the irradiation settings. Moreover, the resumption of cyclic menses after oncological treatment does not guarantee normal fertility [5]. However, studies suggest that cancer survivors do want to have children that are biologically theirs, and some even experience increased value on parenthood because of their experience with cancer [1,2,6–10]. Fertility preservation has therefore become a main issue over the past decades as an integral part of the care for cancer patients, recognizing the importance of fertility in future life.

After fertility preservation became a subject of interest, several procedures were investigated. In our hospital in vitro fertilization

* Corresponding author at: Department of Gynecology, Leiden University Medical Center, K6-67, PO Box 9600, 2300 RC Leiden, The Netherlands. Tel.: +31 715263348; fax: +31 715248181.
E-mail addresses: l.a.louwe@lumc.nl, l.a.louwe@planet.nl (L.A. Louwe).
[1] Esther Jenninga passed away on 15 december 2009.

0301-2115/$ – see front matter © 2011 Elsevier Ireland Ltd. All rights reserved.
doi:10.1016/j.ejogrb.2011.11.011

with embryo cryopreservation, ovarian tissue cryopreservation and transposition of the ovaries are available techniques for fertility preservation. Currently, only ovarian transposition and conventional in vitro fertilization (IVF) with embryo cryopreservation are considered standard treatment options for fertility preservation with reasonable success rates. Although embryo cryopreservation after oocyte retrieval and IVF is an effective and widely available procedure, the necessity of a male partner and time-consuming hormonal stimulation means it is not applicable to single women, or to patients who need to start cancer therapy immediately and it is less suitable in patients with hormone-sensitive malignancies. For those patients, options are limited to experimental approaches like ovarian tissue and oocyte cryopreservation. Although cryopreservation of ovarian tissue prior to gonadotoxic treatments is considered an experimental procedure, nevertheless 14 livebirths after transplanting frozen/thawed ovarian tissue have been reported [11–18]. Cryopreservation of oocytes utilizing vitrification, an ultra-rapid freezing protocol, which avoids ice crystal formation in the cytoplasm, offers future possibilities for restoring fertility, especially in single women [19]. The combination of in vitro maturation (IVM) with oocyte cryopreservation prevents any delay in cancer treatment and avoids risks associated with high estradiol levels in hormone-sensitive tumors [20]. Cryopreservation of oocytes for fertility preservation is not yet available for the indication of fertility preservation in cancer patients in the Netherlands. Surgically transposing the ovaries out of the radiation field before pelvic radiation therapy reduces radiation exposure to the ovaries to 5–10% [21], but transposition is not applicable for patients being treated with chemotherapy. There is controversy about the effects of pharmacologic methods for protecting ovarian function by using gonadotropin analogues [22,23].

There are many variables to take into consideration when deciding upon fertility preservation procedures. These include delaying cancer treatment, surgical complications, ovarian hyperstimulation with high hormone levels, reintroducing cancer cells, low success rates and the experimental nature of some of the fertility preservation procedures. However, it remains very important for the physician to inform the patient about all the different treatments so she may make an informed decision regarding the fertility preservation options. In addition, to preserve the full range of options, fertility preservation procedures should be considered as early as possible during treatment planning [24].

Fertility preservation procedures will always take time regarding the steps of referral, counselling and the procedure itself. Whether delay of cancer treatment for fertility preservation procedures is acceptable or not, is to be discussed by the medical oncologist and the patient. In this descriptive study we retrospectively analysed data on the time intervals between the moment of diagnosis of cancer, the moment of referral to a gynecologist, the moment of consultation with a gynecologist, the moment of finishing of fertility preservation procedures (embryo cryopreservation or ovarian tissue cryopreservation) and the start of chemotherapy.

2. Materials and methods

Thirty-five female cancer patients underwent a procedure to preserve their fertility before the start of chemotherapy as cancer treatment. The study period was between November 2003 and March 2008, in the Leiden University Medical Center (LUMC), the Netherlands. Fertility preservation therapy (FPT) consisted of embryo cryopreservation (EC) or ovarian tissue cryopreservation (OTC). The decision to perform FPT was made by consensus among the referring clinician and the institutional multidisciplinary team, including a medical oncologist, a gynecologist and a surgeon. Preferably, EC was performed. However, in patients without a partner and patients with insufficient time to perform an IVF cycle, ovarian tissue cryopreservation was proposed according to a protocol "Cryopreservation of ovarian tissue". Approval for this protocol and for use of the computerized database of the patients referred for fertility consultation, was obtained from the Institutional Review Board of the Leiden University Medical Center. Informed consent was signed by the patient or a patient's parent in under-age patients.

The ovarian stimulation procedure for hormone-sensitive breast cancer is based on a protocol by Oktay [25]. These patients started on day 2 or 3 of the menstrual cycle with a short protocol of tamoxifen alone or tamoxifen plus low dose follicle stimulating hormone (FSH). However, from August 2007 the protocol of tamoxifen alone was abandoned because of low embryo yield. The standard IVF protocol, FSH plus a gonadotropin-releasing agonist, was applied in patients without a hormone-sensitive tumor [26]. IVF during an unstimulated cycle was considered if hormonal stimulation was contraindicated or after patient non-approval. A single dose of recombinant human chorionic gonadotropin was given when the lead follicle had a mean diameter of 18 mm (measured in two directions). Ultrasound-guided oocyte retrieval was performed 36 h later. IVF was performed via intracytoplasmatic sperm injection and embryos were cryopreserved with a slow freezing protocol until further use.

The OTC procedure consisted of a laparoscopic unilateral oophorectomy under general anesthesia. The oophorectomy was performed by laparotomy if a surgical procedure was already planned. In the operating room the ovarian tissue was dissected into small slices of ovarian cortex (10 mm × 5 mm × 1 mm) according to the description of Radford [27]. The slices were transferred in vials to the IVF laboratory. After cryopreservation with a slow freezing protocol, they were stored in liquid nitrogen, until required. No complications related to the fertility preservation procedures were reported.

Clinical charts and a computerized database were reviewed retrospectively for date of diagnosis, date of referral for fertility consultation, date of first consultation for FPT, date of finishing FPT (in OTC day of operation, in EC day of ovum pick-up) and date of start of chemotherapy. The date of diagnosis was the date on which the histologic diagnosis was definitive.

The Statistical Package for the Social Sciences, SPSS version16 was used to perform descriptive statistics. A comparison between OTC and EC was made by using the Mann–Whitney *U*-test and chi-squared test in the case of respectively continuous or ordinal and nominal variables. p-Value <0.05 was considered statistically significant.

3. Results

3.1. Patients' characteristics

Twelve of the 35 patients (34.3%) opted for IVF in order to cryopreserve embryos (EC), ten patients underwent one, and two patients two IVF cycles. In 9 of the 12 patients who started an IVF cycle, embryos were cryopreserved (median = 4; range 1–16). Ovarian tissue was cryopreserved (OTC) in 23 of the 35 patients (65.7%).

The mean age of the patients undergoing OTC or EC was 29.3 ± 5.8 years (range 14–39). Among the total study group 27 patients were nulligravid, four patients had previous pregnancies with elective terminations ($n = 2$) or miscarriages ($n = 2$). Four patients had full-term pregnancies prior to FPT. All patients undergoing EC were diagnosed with invasive ductal carcinoma of the breast. In the OTC group 14 patients were diagnosed with invasive